Bulky Polar Additives That Greatly Reduce the Viscosity of Concentrated Solutions of Therapeutic Monoclonal Antibodies.
J Pharm Sci
; 106(5): 1211-1217, 2017 05.
Article
en En
| MEDLINE
| ID: mdl-28137697
ABSTRACT
The viscosity of concentrated aqueous solutions of 3 clinical monoclonal antibodies (mAbs), Erbitux®, Herceptin®, and Rituxan®, has been reduced up to over 10-fold by adding certain bulky polar additives instead of saline at isotonic levels. Because these additives are also found not to compromise mAbs' stability against aggregation induced by stresses, a drug-delivery modality switch from intravenous infusions to more convenient and inexpensive parenteral options like subcutaneous injections may become possible.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Química Farmacéutica
/
Cetuximab
/
Trastuzumab
/
Anticuerpos Monoclonales
Idioma:
En
Revista:
J Pharm Sci
Año:
2017
Tipo del documento:
Article